Concepedia

Publication | Closed Access

Inhibition of ACAA1 Restrains Proliferation and Potentiates the Response to CDK4/6 Inhibitors in Triple-Negative Breast Cancer

DOI

24

Citations

46

References

2023

Year

Wenting Peng, Xi Jin, Xiao‐En Xu, Yun‐Song Yang, Ding Ma, Zhi‐Ming Shao, Yi‐Zhou Jiang
Cancer Research

Abstract

ACAA1 is highly expressed in TNBC, serving as a potential therapeutic target in ACAA1-high tumors and a predictive biomarker of resistance to CDK4/6 inhibitors for RB1-proficient patients.

References

YearCitations

Comprehensive molecular portraits of human breast tumours

Nature

2012

12.1K

Autophagy fights disease through cellular self-digestion

Noboru Mizushima, Beth Levine, Ana María Cuervo,

Nature

2008

6.4K

Drug Combination Studies and Their Synergy Quantification Using the Chou-Talalay Method

Ting‐Chao Chou

Cancer Research

2010

5.5K

Triple-Negative Breast Cancer: Clinical Features and Patterns of Recurrence

Rebecca Dent, Maureen Trudeau, Kathleen I. Pritchard,

Clinical Cancer Research

2007

5K

Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer

Peter Schmid, Sylvia Adams, Hope S. Rugo,

New England Journal of Medicine

2018

4.2K

DrugBank: a comprehensive resource for in silico drug discovery and exploration

David S. Wishart

Nucleic Acids Research

2005

4K

Olaparib for Metastatic Breast Cancer in Patients with a Germline <i>BRCA</i> Mutation

Mark E. Robson, Seock‐Ah Im, Elżbieta Senkus,

New England Journal of Medicine

2017

3.1K

Pembrolizumab for Early Triple-Negative Breast Cancer

Peter Schmid, Javier Cortés, Lajos Pusztai,

New England Journal of Medicine

2020

2.9K

Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer

Shanu Modi, William Jacot, Toshinari Yamashita,

New England Journal of Medicine

2022

2.3K

Talazoparib in Patients with Advanced Breast Cancer and a Germline <i>BRCA</i> Mutation

Jennifer K. Litton, Hope S. Rugo, Johannes Ettl,

New England Journal of Medicine

2018

2K

Page 1